Key Insights

Highlights

Success Rate

83% trial completion

Published Results

40 trials with published results (20%)

Research Maturity

111 completed trials (54% of total)

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 62/100

Termination Rate

10.8%

22 terminated out of 204 trials

Success Rate

83.5%

-3.1% vs benchmark

Late-Stage Pipeline

21%

43 trials in Phase 3/4

Results Transparency

36%

40 of 111 completed with results

Key Signals

40 with results83% success22 terminated

Data Visualizations

Phase Distribution

122Total
Not Applicable (20)
Early P 1 (1)
P 1 (22)
P 2 (36)
P 3 (28)
P 4 (15)

Trial Status

Completed111
Unknown31
Terminated22
Recruiting15
Withdrawn11
Active Not Recruiting10

Trial Success Rate

83.5%

Benchmark: 86.6%

Based on 111 completed trials

Clinical Trials (204)

Showing 20 of 20 trials
NCT05727540CompletedPrimary

The Cohort Study of Uveitis Patients

NCT07813598RecruitingPrimary

PANDA-ASOCT: Paediatric Anterior Uveitis Detection With Automated Image Analysis Using ASOCT

NCT01859299CompletedPrimary

Intestinal Bacteria and Ocular Inflammatory Disease

NCT06310837Not ApplicableCompletedPrimary

Effect of Immunosuppressants With Adalimumab Biosimilars vs Corticosteroids on Noninfectious Uveitis

NCT05388838Not ApplicableCompletedPrimary

Screening for Oculocerebral Lymphoma With the Phenotype of NK Cells in Patients With Uveitis

NCT02656381CompletedPrimary

Uveitis/Intraocular Inflammatory Disease Biobank (iBank)

NCT07773623Phase 4Active Not RecruitingPrimary

An Interventional Study of Upadacitinib Extended-Release Tablets in Patients With Refractory Uveitis

NCT07547995Phase 2RecruitingPrimary

A Study of Efficacy and Safety of GenSci048 in Subjects With Active Uveitis.

NCT06974162RecruitingPrimary

Metagenomics for Ocular Inflammation

NCT06390436Phase 4Not Yet RecruitingPrimary

Therapeutic Drug Monitoring-baSed adalimuMab De-escalatiOn in nOn-infecTious cHronic Uveitis

NCT05286203Not ApplicableCompletedPrimary

Ocular Pathogen and Transcriptome Investigation Using Comprehensive Sequencing

NCT07518134RecruitingPrimary

A Study of Uveitis in Children <18 Years of Age

NCT04088409Phase 3Active Not RecruitingPrimary

A Study of Baricitinib (LY3009104) in Participants From 2 Years to Less Than 18 Years Old With Active JIA-Associated Uveitis or Chronic Anterior Antinuclear Antibody-Positive Uveitis

NCT06273748RecruitingPrimary

RChildUV:Study on Non-infectious Chronic Uveitis in Pediatric Age

NCT01746537RecruitingPrimary

Analysis of Anterior Chamber Inflammation by Optical Coherence Tomography

NCT04704609Active Not RecruitingPrimary

Imaging Quantification of Inflammation (IQI)

NCT02357238RecruitingPrimary

Genetics of Uveitis

NCT04340505CompletedPrimary

Imaging of Uveitis Patients Receiving Injectable Fluocinolone Acetonide Implant

NCT02998398Completed

Evaluation of the Switch From the Original Infliximab to Its Biosimilar in Daily Practice at Cochin Hospital

NCT06431373Phase 3Active Not Recruiting

A Study of Brepocitinib in Adults With Active, Non-Infectious, Non-Anterior Uveitis

Scroll to load more

Research Network

Activity Timeline